Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Rating of “Moderate Buy” by Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $42.7273.

Several research analysts have recently commented on the company. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th.

Pharvaris Trading Down 5.1%

Shares of PHVS opened at $29.44 on Friday. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -8.74 and a beta of -2.34. The stock has a 50 day moving average of $27.62 and a 200-day moving average of $26.03. Pharvaris has a 52 week low of $14.59 and a 52 week high of $31.14.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, sell-side analysts predict that Pharvaris will post -3.19 earnings per share for the current fiscal year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six?figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near?term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ?$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ?$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ?$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Insider Buying and Selling

In related news, insider Anne Lesage sold 21,700 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.26, for a total transaction of $656,642.00. Following the completion of the transaction, the insider directly owned 56,450 shares in the company, valued at $1,708,177. This represents a 27.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Berndt Modig sold 23,333 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total value of $647,257.42. Following the transaction, the chief executive officer owned 142,084 shares of the company’s stock, valued at approximately $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 150,659 shares of company stock valued at $4,489,587 in the last 90 days. Corporate insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL bought a new position in Pharvaris during the 3rd quarter worth $1,943,000. Patient Square Capital LP grew its stake in Pharvaris by 41.4% during the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after buying an additional 101,098 shares during the last quarter. Boothbay Fund Management LLC grew its stake in Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after buying an additional 23,743 shares during the last quarter. Finally, General Atlantic L.P. grew its stake in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.